Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 26427914)

  • 1. Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer.
    Giordano G; Febbraro A; Tomaselli E; Sarnicola ML; Parcesepe P; Parente D; Forte N; Fabozzi A; Remo A; Bonetti A; Manfrin E; Ghasemi S; Ceccarelli M; Cerulo L; Bazzoni F; Pancione M
    J Exp Clin Cancer Res; 2015 Oct; 34():108. PubMed ID: 26427914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
    Derangère V; Fumet JD; Boidot R; Bengrine L; Limagne E; Chevriaux A; Vincent J; Ladoire S; Apetoh L; Rébé C; Ghiringhelli F
    Oncotarget; 2016 Feb; 7(8):9309-21. PubMed ID: 26824184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.
    Troiani T; Napolitano S; Vitagliano D; Morgillo F; Capasso A; Sforza V; Nappi A; Ciardiello D; Ciardiello F; Martinelli E
    Clin Cancer Res; 2014 Jul; 20(14):3775-86. PubMed ID: 24812410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased fucosylation has a pivotal role in multidrug resistance of breast cancer cells through miR-224-3p targeting FUT4.
    Feng X; Zhao L; Gao S; Song X; Dong W; Zhao Y; Zhou H; Cheng L; Miao X; Jia L
    Gene; 2016 Mar; 578(2):232-41. PubMed ID: 26701615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High early growth response 1 (EGR1) expression correlates with resistance to anti-EGFR treatment in vitro and with poorer outcome in metastatic colorectal cancer patients treated with cetuximab.
    Kumar SS; Tomita Y; Wrin J; Bruhn M; Swalling A; Mohammed M; Price TJ; Hardingham JE
    Clin Transl Oncol; 2017 Jun; 19(6):718-726. PubMed ID: 28005260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
    Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
    Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer.
    Arai H; Millstein J; Loupakis F; Stintzing S; Wang J; Battaglin F; Kawanishi N; Jayachandran P; Soni S; Zhang W; Mumenthaler SM; Cremolini C; Heinemann V; Falcone A; Lenz HJ
    Eur J Cancer; 2021 Jun; 150():133-142. PubMed ID: 33901792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of optimal drug sequencing in metastatic colorectal cancer: biological rationales for the observed survival benefit conferred by first-line treatment with EGFR inhibitors.
    Wainberg ZA; Drakaki A
    Expert Opin Biol Ther; 2015; 15(8):1205-20. PubMed ID: 26066903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab.
    Sagawa T; Sato Y; Hirakawa M; Hamaguchi K; Fukuya A; Okamoto K; Miyamoto H; Muguruma N; Fujikawa K; Takahashi Y; Takayama T
    Sci Rep; 2020 Nov; 10(1):19815. PubMed ID: 33188279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential expression of LeY and fucosyltransferase IV correlates with the receptivity of RL95-2 and HEC-1A human uterine epithelial cells.
    Liu S; Yang X; Wang J; Wei J; Zhang D; Wang X; Yan Q
    Cell Biol Int; 2012 May; 36(5):469-74. PubMed ID: 22145955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab.
    Pander J; Heusinkveld M; van der Straaten T; Jordanova ES; Baak-Pablo R; Gelderblom H; Morreau H; van der Burg SH; Guchelaar HJ; van Hall T
    Clin Cancer Res; 2011 Sep; 17(17):5668-73. PubMed ID: 21788356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asparaginyl endopeptidase contributes to cetuximab resistance via MEK/ERK signaling in RAS wide-type metastatic colorectal cancer.
    Xu X; Liu M; Peng K; Yu Y; Liu T
    Clin Transl Oncol; 2023 Mar; 25(3):776-785. PubMed ID: 36609651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.
    Holch JW; Ricard I; Stintzing S; Modest DP; Heinemann V
    Eur J Cancer; 2017 Jan; 70():87-98. PubMed ID: 27907852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and validation of cetuximab resistance associated long noncoding RNA biomarkers in metastatic colorectal cancer.
    Peng K; Liu R; Yu Y; Liang L; Yu S; Xu X; Liu T
    Biomed Pharmacother; 2018 Jan; 97():1138-1146. PubMed ID: 29136952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK.
    Martinelli E; Morgillo F; Troiani T; Ciardiello F
    Cancer Treat Rev; 2017 Feb; 53():61-69. PubMed ID: 28073102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclophosphamide-induced apoptosis in A431 cells is inhibited by fucosyltransferase IV.
    Yang X; Liu Y; Liu J; Wang X; Yan Q
    J Cell Biochem; 2011 May; 112(5):1376-83. PubMed ID: 21337384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models.
    Belli V; Matrone N; Napolitano S; Migliardi G; Cottino F; Bertotti A; Trusolino L; Martinelli E; Morgillo F; Ciardiello D; De Falco V; Giunta EF; Bracale U; Ciardiello F; Troiani T
    J Exp Clin Cancer Res; 2019 Jun; 38(1):236. PubMed ID: 31164152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
    Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer.
    Giordano G; Parcesepe P; D'Andrea MR; Coppola L; Di Raimo T; Remo A; Manfrin E; Fiorini C; Scarpa A; Amoreo CA; Conciatori F; Milella M; Caruso FP; Cerulo L; Porras A; Pancione M
    J Exp Clin Cancer Res; 2019 Jan; 38(1):28. PubMed ID: 30670049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab.
    Prewett M; Deevi DS; Bassi R; Fan F; Ellis LM; Hicklin DJ; Tonra JR
    Clin Cancer Res; 2007 Dec; 13(24):7432-40. PubMed ID: 18094427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.